NovaBridge Biosciences (NBP) Current Leases (2019 - 2026)
NovaBridge Biosciences (NBP) posted quarterly Current Leases of $891000.0 for Q4 2025, up 9.19% year-over-year from $816000.0 in Q4 2024, and up 2.18% quarter-over-quarter from $872000.0 in Q3 2025.
Powered by 
Analysis
NovaBridge Biosciences (NBP) Current Leases (2019 - 2026) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Current Leases for 7 consecutive years, with $891000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Current Leases rose 9.19% year-over-year to $891000.0; the TTM figure through Dec 2025 stood at $891000.0 (up 9.19% YoY), while the FY2025 annual figure was $891000.0, up 9.19% from the prior year.
- Current Leases advanced to $891000.0 in Q4 2025 per NBP's latest filing, from $872000.0 in the prior quarter.
- Across five years, Current Leases topped out at $4.8 billion in Q4 2021 and bottomed at $737000.0 in Q2 2024.
- Historically, Current Leases has averaged $370.8 million across 5 years, with a median of $891000.0 in 2025.
- Annual changes were most pronounced in 2021 — Current Leases jumped 394417.06% — and 2022, when it sank 99.93%.
- NovaBridge Biosciences' Current Leases stood at $4.8 billion in 2021, then tumbled by 99.93% to $3.4 million in 2022, then dropped by 9.76% to $3.0 million in 2023, then plunged by 73.16% to $816000.0 in 2024, then advanced by 9.19% to $891000.0 in 2025.
- Business Quant data shows NBP's Current Leases at $891000.0 in Q4 2025, $872000.0 in Q3 2025, and $853000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.27 Mn |
| 10 | NovaBridge Biosciences | 197.68 Mn | 197.68 Mn | - | 1.28 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.28 Mn |
| Dec 31, 2025 | 891,000.00 |
| Sep 30, 2025 | 872,000.00 |
| Jun 30, 2025 | 853,000.00 |
| Mar 31, 2025 | 835,000.00 |
| Dec 31, 2024 | 816,000.00 |
| Sep 30, 2024 | 753,000.00 |
| Jun 30, 2024 | 737,000.00 |
| Dec 31, 2023 | 3.04 Mn |
| Jun 30, 2023 | 3.77 Mn |
| Dec 31, 2022 | 3.37 Mn |
| Jun 30, 2022 | 6.35 Mn |
| Dec 31, 2021 | 4.80 Mn |
| Jun 30, 2021 | 1.53 Mn |
| Dec 31, 2020 | 1.22 Mn |
| Sep 30, 2020 | 1.18 Mn |
| Jun 30, 2020 | 1.16 Mn |
| Dec 31, 2019 | 965,782.40 |